Dimitrios Papagiannidis

Biotransformation of synthetic steroid drugs by gut and environmental bacteria affects their activity within the host, persistence, and environmental fate of these widely used pharmaceuticals. However, the spectrum of bacterial transformation of synthetic steroids, the enzymes involved, and the role of cooperative microbial metabolism in these processes remain poorly understood. We systematically mapped the biotransformation of 22 steroids, comprising 20 synthetic and 2 natural compounds and spanning clinically used estrogens, progestogens, corticosteroids, and prodrugs, across 12 bacterial species (8 intestinal and 4 environmental), yielding 264 steroid-bacteria combinations. We identified 97 unique biotransformation products and found that the tested bacteria catalyze diverse reactions including ester hydrolysis, oxidation-reduction chemistry, and steroid side-chain cleavage. Notably, the environmental bacterium Sphingobium herbicidovorans catalyzed desmolase-like steroid side-chain cleavage under aerobic conditions, a transformation previously reported solely for anaerobic bacteria. Combining sequence homology searches, a genetic gain-of-function screen, and expression proteomics we identified six steroid-transforming enzymes in S. herbicidovorans. We further demonstrate that distinct bacterial species cooperatively metabolize synthetic steroids through cross-feeding, enabling sequential activation and metabolism of corticosteroids across microbial communities. Together, our findings uncover previously unrecognized bacterial enzymes and community-level interactions involved in synthetic steroid metabolism. By directly linking steroid metabolites, enzymes, and microbial community interactions, this study provides molecular-level mechanistic insights into microbial steroid biotransformation. Such insights are essential for ultimately predicting metabolic interactions within and across microbial communities, as well as their interactions with the host and the environment.

Biotransformation of synthetic steroid drugs by gut and environmental bacteria shapes the activity within the host, persistence, and environmental fate of these widely used pharmaceuticals. However, the scope of bacterial transformations of synthetic steroids, the enzymes involved, and the role of microbial cooperative metabolism in these processes remain poorly understood. Here, we systematically investigated the biotransformation of 20 synthetic and 2 natural steroids, including clinically relevant estrogens, progestogens, corticosteroids, and prodrugs, across 8 intestinal and 4 environmental bacterial species. We identified more than 130 biotransformation products and found that the tested bacteria catalyzed diverse reactions including ester hydrolysis, oxidation-reduction chemistry, and steroid side-chain cleavage. Notably, the aerobic environmental bacterium Sphingobium herbicidovorans catalyzed desmolase-like steroid side-chain cleavage, a transformation not previously reported in aerobic bacteria. Combining homology searches, gain-of-function screening, and expression proteomics we identified six steroid-transforming enzymes in S. herbicidovorans. We further demonstrated that distinct bacterial species cooperatively metabolize synthetic steroids through interspecies metabolic cross-feeding, enabling sequential activation and metabolism of corticosteroids across microbial communities. Together, our findings uncover previously unrecognized bacterial enzymes and community-level interactions involved in synthetic steroid metabolism, directly linking metabolites, enzymes, and community interactions and establishing microbial biotransformation as an important determinant of steroid drug fate in host-associated and environmental ecosystems, where mechanistic resolution of bacterial steroid pathways is essential to predict metabolic interactions within and across microbial communities.

Antibiotic resistant pathogens are an increasing public health threat, as development of novel therapeutics is outpaced by resistance emergence and dissemination. Approaches to slow down or even revert antibiotic resistance are necessary to maintain efficacy of both existing and new antibiotics. Such approaches exploit the fitness cost of resistance elements, but have largely relied on assessing this cost in laboratory conditions that poorly reflect the native context in which pathogens reside. Here we present a method that allows to investigate the influence of personalized human gut microbiota compositions on the competitive fitness of antibiotic resistant pathogens. Using fecal matter-derived microbiomes we identified a specific community that selected for a carbapenem-resistant Klebsiella pneumoniae strain. This selective advantage was due to mutations arising in a LacI-type transcriptional regulator, GlyR, which upregulated expression of the downstream glycoporin GlyP, causing the effect. By deconvoluting the microbiome composition, we identified a focal E. coli strain as a central driver of the selection, which was further modulated by other microbiota members. We further demonstrate that the selective advantage was due to carbohydrate competition, and in particular for glycerol-containing compounds. Importantly, glyR mutations are under strong positive but conditional selection in clinical K. pneumoniae isolates. This implies a reduced competitiveness in other environments, which we experimentally validated in vitro . Overall, this study offers a path to identify microbiome-specific interactions that modulate the competitiveness of antibiotic resistant pathogens.

Dysregulated kinase activity drives oncogenic signaling, disrupts cellular homeostasis, and promotes tumour progression. The BRAFV600E mutation constitutively activates the MAPK pathway and is a key therapeutic target in melanoma and other cancers, but the functional relevance of most downstream phosphorylation events and mechanisms of drug resistance remain unclear. To address this, a global multi-omic model of BRAF inhibition response was established in BRAFV600E-mutant cells by integrating time-resolved and biophysical phosphoproteomics, transcriptomics, and thermal proteome profiling. Ultradeep phosphoproteomics revealed extensive phosphorylation changes upon BRAF inhibitor treatment, while biophysical phosphoproteomics identified phosphorylation events linked to altered protein solubility and subcellular localization, suggesting changes in nucleic acid interactions and nuclear reorganisation. Network-based integration of these datasets prioritized functionally relevant phosphorylation sites and kinases. Experimental validation identified CDK9, CLK3, and TNIK as critical regulators of BRAFV600E signaling and candidate targets for combinatorial inhibition capable of re-sensitising resistant cells. The transcription factor ETV3 emerged as a previously unrecognised effector of BRAF signaling. Biophysical proteomics data confirmed that ETV3 phosphorylation modulates DNA-binding, while functional assays combining knockdown, metabolomics, and drug screening demonstrated its role in coordinating transcriptional and metabolic adaptations to BRAF inhibition. This study provides a systems-level framework linking phosphorylation dynamics to protein function and phenotype, identifies ETV3 as a new node in oncogenic BRAF signaling, and illustrates how integrated, site-resolved models can reveal mechanisms of kinase-driven oncogenesis. Highlights: Time- and cell type-resolved phosphoproteomics maps BRAF inhibition dynamics Biophysical phosphoproteomics, combining quantitative phosphoproteomics with solubility profiling or nuclear fractionation, reveals phosphorylation-driven changes of protein solubility and localization Integration of abundance and biophysical phosphoproteomics data identifies functionally relevant phosphorylation events of BRAFV600E signaling Network integration of multimodal phosphoproteomic, transcriptomic and thermal proteome profiling data links signaling to protein function and cellular phenotypes Biophysical evidence improves models and identifies non-canonical kinases driving BRAF signaling as well as novel downstream regulators such as ETV3 Follow-up experiments reveal a ETV3-GLUT3-mediated metabolic adaptation in BRAFV600E cells

Per- and polyfluoroalkyl substances (PFAS) are persistent pollutants that pose major environmental and health concerns. While few environmental bacteria have been reported to bind PFAS, the interaction of PFAS with human-associated gut bacteria is unclear. Here we report the bioaccumulation of PFAS by 38 gut bacterial strains ranging in concentration from nanomolar to 500 μM. Bacteroides uniformis showed notable PFAS accumulation resulting in millimolar intracellular concentrations while retaining growth. In Escherichia coli, bioaccumulation increased in the absence of the TolC efflux pump, indicating active transmembrane transport. Cryogenic focused ion beam secondary-ion mass spectrometry confirmed intracellular localization of the PFAS perfluorononanoic acid (PFNA) in E. coli. Proteomic and metabolomic analysis of PFNA-treated cells, and the mutations identified following laboratory evolution, support these findings. Finally, mice colonized with human gut bacteria showed higher PFNA levels in excreted faeces than germ-free controls or those colonized with low-bioaccumulating bacteria. Together, our findings uncover the high PFAS bioaccumulation capacity of gut bacteria.

Per- and polyfluoroalkyl Substances (PFAS) – the so-called ‘forever chemicals’ – are a major cause of environmental and health concern due to their toxicity and long-term persistence ^1,2 . Yet, no efficient mechanisms for their removal have been identified. Here we report bioaccumulation of PFAS by several gut bacterial species over a wide range of concentrations from nanomolar up to 500 μM. For bioaccumulating Bacteroides uniformis, a highly prevalent species, we estimate intracellular PFAS concentration in the mM range – above that of most native metabolites. Despite this high bioaccumulation, B. uniformis cells could grow appreciably up to 250 μM perfluorononanoic acid (PFNA) exposure. Escherichia coli, which accumulated PFAS to a much lesser extent, substantially increased PFAS bioaccumulation when lacking TolC efflux pump indicating trans-membrane transport in PFAS bioaccumulation. Electron microscopy and cryogenic Focused Ion Beam-Secondary Ion Mass-spectrometry revealed distinct morphological changes and intracellular localisation of PFNA aggregates. Bioaccumulation of PFAS and transmembrane transport is also evident in proteomics, metabolomics, thermal proteome profiling, and mutations following adaptive laboratory evolution. In an in vivo context, mice colonized with human gut bacteria showed, compared to germ-free controls or those colonized with low-bioaccumulating bacteria, higher PFNA levels in excreted feces. As the gut microbiota is a critical interface between exposure and human body, our results have implications for understanding and utilizing microbial contribution to PFAS clearance.

RNA-binding proteins (RBPs) are central components of gene regulatory networks. The differentiation of heterocysts in filamentous cyanobacteria is an example of cell differentiation in prokaryotes. Although multiple non-coding transcripts are involved in this process, no RBPs have been implicated thus far. Here we used quantitative mass spectrometry to analyze the differential fractionation of RNA-protein complexes after RNase treatment in density gradients yielding 333 RNA-associated proteins, while a bioinformatic prediction yielded 311 RBP candidates in Nostoc sp. PCC 7120. We validated in vivo the RNA-binding capacity of 6 RBP candidates. Some participate in essential physiological aspects, such as photosynthesis (Alr2890), thylakoid biogenesis (Vipp1) or heterocyst differentiation (PrpA, PatU3), but their association with RNA was unknown. Validated RBPs Asl3888 and Alr1700 were not previously characterized. Alr1700 is an RBP with two OB-fold domains that is differentially expressed in heterocysts. Deletion of alr1700 led to complete deregulation of the cell differentiation process, a striking increase in the number of heterocyst-like cells, and was ultimately lethal in the absence of combined nitrogen. These observations characterize this RBP as a master regulator of the heterocyst patterning and differentiation process, leading us to rename Alr1700 to PatR. The data can be accessed at https://sunshine.biologie.uni-freiburg.de/R-DeeP-Nostoc/ .

EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

A colorimetric isothermal RNA amplification method was shown to detect SARS-CoV-2 RNA in clinical samples with excellent sensitivity and specificity.

The COVID-19 pandemic caused by the novel SARS-CoV-2 virus poses a significant public-health problem. In order to control the pandemic, rapid tests for detecting existing infections and assessing virus spread are critical. Approaches to detect viral RNA based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) hold outstanding promise towards greatly simplified and broadly applicable testing methods. RT-LAMP assays appear more robust than qPCR-based methods and only require incubation at a constant temperature, thus eliminating the need for sophisticated instrumentation. Here, we tested a two-color RT-LAMP protocol using clinical SARS-CoV-2 samples and also established a protocol that does not require prior RNA isolation (“swab-to-RT-LAMP”). Our study is based on several hundred clinical patient samples with a wide range of viral loads, thus allowing, for the first time, to accurately determine the sensitivity and specificity of the RT-LAMP assay for the detection of SARS-CoV-2 in patients. We found that RT-LAMP can reliably detect SARS-CoV-2 samples with a qPCR threshold cycle number (CT value) of up to 30 in the standard RT-qPCR assay. We used both, either purified RNA or direct pharyngeal swab specimens and showed that RT-LAMP assays have, despite a decreased sensitivity compared to RT-qPCR, excellent specificity. We also developed a multiplexed LAMP-sequencing protocol as a diagnostic and validation procedure to detect and record the outcome of RT-LAMP assays. LAMP-sequencing is fully scalable and can assess the results of thousands of LAMP reactions in parallel. Finally, we propose applications of RT-LAMP based assays for SARS-CoV-2 detection.